Lana

That's worth paying attention to, no matter where you live.

That's it for today.

I'm Lana.

I'll see you tomorrow.

Hey, I'm Lana with your Daily Brief for Saturday, February 7th.

Coming up, investors changed their minds about a former safe bet, refusing to buy the software sector's stocks or lend its firms cash.

And the U.S.

government's new drug platform could mean cheaper medicine for you and discounted pharma stocks, too.

We'll also check in with Carl to get his answers to your burning questions.

More on the way, but first, a word from Guy at Phenomize HQ.

Investors had already dipped out of some software stocks, and now they're nervous about lending the sector's firms money too.

You can tell because the prices of software loans and bonds are falling, indicating that folks now see the companies as riskier bets and want higher returns to compensate.

That's a red flag.

See, debt investors are typically quite unflappable, focusing on whether a company will still be standing and paying its bills years down the line.

So their concern doesn't exactly bode well for the industry.

What's worse, software businesses now make up one of the biggest slices of the corporate loan market.

So if this crack in confidence grows, it could bleed into the broader borrowing world.

If investors pull more money from loan funds, those funds may be forced to sell their holdings, pushing prices down and borrowing costs up even more.

Now, defaults are still low, so this isn't a crisis yet.

But as investors shift their focus from flashy growth to solid finances, it'll only get harder and more expensive for weaker firms to borrow cash.